Aspirin and other non-steroidal anti-inflammatory drugs as cyclooxygenase inhibitors: State of the art, barriers and perspectives

Current Computer-Aided Drug Design

Volumn 5, Issue 1, 2009, Pages 1-12

  Avram, Speranta ^a   Duda Seiman, Daniel M ^b   Svab, Istvan ^a   Mancas, Silvia ^b   Duda Seiman, Corina ^c   Mihailescu, Dan F ^a  

^a UNIVERSITY OF BUCHAREST   (Romania)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c WEST UNIVERSITY OF TIMISOARA   (Romania)

Author keywords

Cyclooxygenase inhibitors; Molecular simulation; Non steroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

BIOACTIVITY; COMPUTATIONAL CHEMISTRY; HYDROPHOBICITY; MOLECULAR GRAPHICS; MOLECULAR STRUCTURE;

CARDIOPROTECTIVE EFFECT; CYCLOOXYGENASE INHIBITOR; CYCLOOXYGENASES; ISOFORMS; MOLECULAR SIMULATIONS; NON-STEROIDAL ANTI-INFLAMMATORY DRUG; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; PROPERTY; RESEARCH INTERESTS; STATE OF THE ART;

PLATELETS;

1,5 DIARYLPYRROLE 3 ALKOXYETHYL ETHER DERIVATIVE; 1,5 DIARYLPYRROLE DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [5 (4 BROMOPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 ARYL 2,2 DIALKYL 4 PHENYL 3(2H) FURANONE DERIVATIVE; 7 TERT BUTYL 2,3 DIHYDRO 3,3 DIMETHYLBENZOFURAN DERIVATIVE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTITHROMBOCYTIC AGENT; BENZOFURAN DERIVATIVE; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRIDAMOLE; ETHER DERIVATIVE; FLURBIPROFEN; FURANONE DERIVATIVE; INDOMETACIN; ISOENZYME; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HUMAN; HYDROPHOBICITY; HYPERALGESIA; INFLAMMATION; INFLAMMATORY DISEASE; LIPOPHILICITY; LOW DRUG DOSE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; NONHUMAN; PATIENT COMPLIANCE; PAW EDEMA; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIMULATION; THROMBOCYTE ACTIVATION; THROMBOSIS;

EID: 65649121184     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340909787580872     Document Type: Review

References (75)

1. Patrono, C.; Rocca, B. Aspirin: Promise and resistance in the new millennium. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 25-32.
2. Maclagan, T.J. The treatment of acute rheumatism by salicin. Lancet, 1876, 1, 342-383.
3. Vane, J.R.; Botting, R.M. The mechanism of action of aspirin. Thromb. Res., 2003, 110, 255-258.
4. Dreser, H. Pharmacologisches uber Aspirin (Acetylsalicylsaure). Pflugers Arch., 1899, 76, 306-318.
5. Patrignani, P.; Capone, M.L.; Tacconelli, S. NSAIDs and cardiovascular disease. Heart, 2008, 94, 395-397.
6. Patrono, C.; Coller, B.; Fitzgerald, G.A.; Hirsh, J.; Roth, G. Platelet-active drugs: The relationship among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126, 234-264.
7. Nutiu, R.; Bolcu, C.; Modra, D.; Albulescu, M.; Iagher, R.; Seiman, C. Practice in organic chemistry, 2nd vol. (in Romanian). Eurostampa Publishing House, Timişoara, 2003, 37.
8. Rumore, M.M.; Aron, S.M.; Hiross, E.J. A review of mechanism of action of aspirin and its potential as an immunomodulating agent. Med. Hypotheses, 1987, 22, 387-400.
9. Morely, J. Mechanism of action of aspirin in inflammation. Proc. Roy. Soc. Med., 1977, 70, 32-36.
10. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 1971, 231, 232-235.
11. Vane, J.; Botting, R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J., 1987, 1, 89-96.
12. Wu, K.K. Aspirin and salicylate: An old remedy with a new twist. Circulation, 2000, 102, 2022-2023.
13. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
14. Awtry, E.H.; Loscalzo, J. Aspirin. Circulation, 2000, 101, 1206-1218.
15. Husain, S.; Andrews, N.P.; Mulcahy, D.; Panza, J.A.; Quyyumi, A.A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation, 1998, 97, 716-720.
16. Steer, K.A.; Wallace, T.M.; Bolton, C.H.; Hartog, M. Aspirin protects low density lipoprotein from oxidative modification. Heart, 1997, 77, 333-337.
17. Chandrasekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tomsik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA, 2002, 99, 13926-13931.
18. Schwab, J.M.; Beiter, T.; Linder, J.U.; Laufer, S.; Schulz, J.E.; Meyermann, R.; Schluesener, H.J. COX-3 - a virtual pain target in humans? FASEB J., 2003, 17, 2174-2175.
19. Campbell, C.L.; Smyth, S.; Montalescot, G.; Steinhubl, S.R. Aspirin dose for the prevention of cardiovascular disease. JAMA, 2007, 297, 2018-2024.
20. Biondi-Zoccai, G.; Lotrionte, M. Aspirin resistance in cardiovascular disease carries a worse prognosis, but may indicate pre-existing higher risk. BMJ, 2008, 336, 166-167.
21. Krasopoulos, G.; Brister, S.J.; Beattie, W.S.; Elliot, R.F.; Buchanan, M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008, 336, 195-198.
22. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med., 2007, 357, 2482-2494.
23. Snoep, J.D.; Hovens, M.M.C.; Eikenboom, J.C.J.; van der Bom, J.G.; Huisman, M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch. Intern. Med., 2007, 167, 1593-1599.
24. Freedman, J.E. The aspirin resistance controversy: Clinical entity or platelet heterogeneity? Circulation, 2006, 113, 2865-2867.
25. Maree, A.O.; Curtin, R.J.; Dooley, M.; Conroy, R.M.; Crean, P.; Cox, D.; Fitzgerald, D.J. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol., 2005, 46, 1258-1263.
26. Ridker, P.M.; Cook, N.R.; Lee, I.M.; Gordon, D.; Gaziano, J.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005, 352, 1293-1304.
27. Michelson, A.D.; Cattaneo, M.; Eikelboom, J.W.; Gurbel, P.; Kottke-Marchant, K.; Kunicki, T.J.; Pulcinelli, F.M.; Cerletti, C.; Rao, A.K. On behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of The International Society on Thrombosis and Haemostasis. J. Thromb. Haemost., 2005, 3, 1309-1311.
28. Patrono, C.; García Rodríguez, L.A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., 2005, 353, 2373-2383.
29. Hansson, L.; Zanchetti, A.; Carruthers, S.G.; Dahlof, B.; Elmfeldt, D.; Julius, S.; Menard, J.; Rahn, K.H.; Wedel, H.; Westerling, S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1998, 351, 1755-1762.
30. Peto, R.; Gray, R.; Collins, R.; Wheatley, K.; Hennekens, C.; Jamrozik, K.; Warlow, C.; Hafner, B.; Thompson, E.; Norton, S.; Gilliland, J.; Doll, R. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. (Clin. Res. Ed.), 1988, 296, 313-316.
31. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med., 1989, 321, 129-1235.
32. The Medical Research Council's General Practice Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in primary prevention of ischaemic heart disease in men at increased risk. Lancet, 1998, 351, 233-2341.
33. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomized trial in general practice. Lancet, 2001, 357, 89-95.
34. Sanmuganathan, P.S.; Ghahramani, P.; Jackson, P.R.; Wallis, E.J.; Ramsay, L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis or randomised trials. Heart, 2001, 85, 265-271.
35. Berger, J.S.; Roncaglioni, M.C.; Avanzini, F.; Pangrazzi, I.; Tognoni, G.; Brown, D.L. Aspirin for the primary prevention of cardiovascular events in women and men. A specific meta-analysis of randomized controlled trials. JAMA, 2006, 295, 306-313.
36. Greving, J.P.; Buskens, E.; Koffijberg, H.; Algra, A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation, 2008, 117, 2875-2883.
37. Mosca, L. Aspirin chemoprevention: One size does not fit all. Circulation, 2008, 117, 2844-2846.
38. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
39. Buse, J.B.; Ginsberg, H.N.; Bakris, G.L.; Clark, N.G.; Costa, F.; Eckel, R.; Fonseca, V.; Gerstein, H.C.; Grundy, S.; Nesto, R.W.; Pignone, M.P.; Plutzky, J.; Porte, D.; Redberg, R.; Stitzel, K.F.; Stone, N.J. American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 2007, 30, 162-172.
40. Ryden, L.; Standl, E.; Bartnik, M.; Van den Berghe, G.; Betteridge, J.; de Boer, M.J.; Cosentino, F.; Jonsson, B.; Laakso, M.; Malmberg, K.; Priori, S.; Ostergren, J.; Tuomilehto, J.; Thrainsdottir, I.; Vanhorebeek, I.; Stramba-Badiale, M.; Lindgren, P.; Qiao, Q.; Priori, S.G.; Blanc, J.J.; Budaj, A.; Camm, J.; Dean, V.; Deckers, J.; Dickstein, K.; Lekakis, J.; McGregor, K.; Metra, M.; Morais, J.; Osterspey, A.; Tamargo, J.; Zamorano, J.L.; Deckers, J.W.; Bertrand, M.; Charbonnel, B.; Erdmann, E.; Ferrannini, E.; Flyvbjerg, A.; Gohlke, H.; Juanatey, J.R.; Graham, I.; Monteiro, P.F.; Parhofer, K.; Pyorala, K.; Raz, I.; Schernthaner, G.; Volpe, M.; Wood, D. Task Force on Diabetes, Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J., 2007, 28, 88-136.
41. Nicolucci, A.; de Berardis, G.; Sacco, M.; Tognoni, G. AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: How the same data generate divergent conclusions. Eur. Heart J., 2007, 28, 1926-1927.
42. Belch, J.; MacCuish, A.; Campbell, I.; Cobbe, S.; Taylor, R.; Prescott, R.; Lee, R.; Bancroft, J.; MacEwan, S.; Shepherd, J.; Macfarlane, P.; Morris, A.; Jung, R.; Kelly, C.; Connacher, A.; Peden, N.; Jamieson, A.; Matthews, D.; Leese, G.; McKnight, J.; O'Brien, I.; Semple, C.; Petrie, J.; Gordon, D.; Pringle, S.; MacWalter, R.; and Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, and Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 2008, 337, 1840.
43. Dunn, J.D. Managed care considerations. Am. J. Manag. Care, 2008, 14, 227-237.
44. Sprigg, N.; Gray, L.J.; England, T.; Willmot, M.R.; Zhao, L.; Sare, G.M.; Bath, P.M.W. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: Safety, tolerability and feasibility. PLoS ONE, 2008, 3, 2852.
45. Turley, A.J.; Roberts, A.P.; Morley, R.; Thornley, A.R.; Owens, W.A.; de Belder, M.A. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: The need for targeted follow-up. Interact. CardioVasc. Thorac. Surg., 2008, 7, 231-234.
46. Gresele, P.; Morni, S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc. Drug Rev., 2006, 24, 148-1468.
47. Fiorucci, S.; Mencarelli, A.; Meneguzzi, A.; Lechi, A.; Renga, B.; del Soldato, P.; Morelli, A.; Minuz, P. Co-administration of nitric oxide-aspirin (NCX 4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J. Am. Coll. Cardiol., 2004, 44, 635-641.
48. Turnbull, C.M.; Cena, C.; Fruttero, R.; Gasco, A.; Rossi, A.G.; Megson, I.L. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br. J. Pharmacol., 2006, 148, 517-526.
49. Turnbull, C.M.; Marcarino, P.; Sheldrake, T.A.; Lazzarato, L.; Cena, C.; Fruttero, R.; Gasco, A.; Fox, S.; Megson, I.L.; Rossi, A.G. A novel hybrid aspirin-NO-releasing compound inhibits TNPalpha release from LPS-activated human monocytes and macrophages. J. Inflamm., 2008, 5, 12.
50. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: A comprehensive analysis. Drug Dev. Res., 2005, 64, 220-231.
51. Kalgutkar, A.S.; Marnett, A.B.; Crews, B.C.; Remmel, R.P.; Marnett, L.J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem., 2000, 43, 2860-2870.
52. Kant, G.; Parate, A.; Chaturvedi, S.C. 2D-QSAR study of indomethacin ester derivatives as cyclooxygenase-2 inhibitors. Indian J. Pharm. Sci., 2006, 68, 826-829.
53. Gupta, A.K.; Gupta, R.A.; Soni, L.K.; Kaskhedikar, S.G. Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors. Eur. J. Med. Chem., 2008, 43, 1297-1303.
54. Revathi, S.; Gupta, A.K.; Soni, L.K.; Kavitha, S.; Wagh, R.; Kaskhedikar, S.G. Rationalization of physicochemical characters of 1,5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: A QSAR approach. J. Pharm. Biomed. Anal., 2006, 42, 283-289.
55. Reddy, M.R.; Parrill, A.L. Overview of rational drug design, In Rational drug design: Novel methodology and practical applications; Parrill, A.L.; Reddy, M.R. Eds.; Oxford University Press: Washington, DC, 1999; Vol. ACS symposium series 719, pp. 1-11.
56. Price, M.L.P.; Jorgensen, W.L. Origin of the selectivity of celecoxib analogs with COX-1 and COX-2 from docking and monte carlo simulations. J. Am. Chem. Soc., 2000, 122, 9455-9466.
57. Amaravani, M.; Reddy, R.N.; Reddy, G.V.; Reddanna, P.; Reddy, M.R. A comparison of computer aided drug design methods for calculating relative binding affinities of COX-2 inhibitors. Indian J. Chem., 2006, 45, 174-181.
58. Reddy, R.N.; Mutyala, R.; Aparoy, P.; Reddanna, P.; Rami Reddy, M. Computer aided drug design approaches to develop cyclooxy-genase based novel anti-inflammatory and anti-cancer drugs. Curr. Pharm. Des., 2007, 13, 3505-3517.
59. Oprea, T.I.; Waller, C.L.; Marshall, G.R. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. J. Med. Chem., 1994, 37, 2206-2215.
60. Connolly, M.L. Shape distributions of protein topography. Biopolymers, 1992, 32, 1215-1236.
61. Padron, J.A.; Carrasco, R.; Pellon, R.F. Molecular descriptor based on a molar refractivity partition using Randic-type graphtheoretical invariant. J. Pharm. Pharm. Sci., 2002, 5, 258-266.
62. Keseru, G.M.; Molnar, L. High-throughput prediction of blood-brain partitioning: A thermodynamic approach. J. Chem. Inf. Comput. Sci., 2001, 41, 120-128.
63. Cramer, R.D., 3rd; Patterson, D.E.; Bunce, J.D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res., 1989, 291, 161-165.
64. Ferrara, P.; Gohlke, H.; Price, D.J.; Klebe, G.; Brooks, C.L., 3rd. Assessing scoring functions for protein-ligand interactions. J. Med. Chem., 2004, 47, 3032-3047.
65. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
66. Giordanetto, F.; Cotesta, S.; Catana, C.; Trosset, J.Y.; Vulpetti, A.; Stouten, P.F.; Kroemer, R.T. Novel scoring functions comprising QXP, SASA, and protein side-chain entropy terms. J. Chem. Inf. Comput. Sci., 2004, 44, 882-893.
67. Kurogi, Y.; Guner, O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem., 2001, 8, 1035-1055.
68. Oshiro, C.M.; Kuntz, I.D.; Dixon, J.S. Flexible ligand docking using a genetic algorithm. J. Comput. Aided Mol. Des., 1995, 9, 113-130.
69. Zheng, M.; Zhang, Z.; Zhu, W.; Liu, H.; Luo, X.; Chen, K.; Jiang, H. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): Molecular docking and 3D-QSAR analyses on DHDMBF analogues. Bioorg. Med. Chem., 2006, 14, 3428-3437.
70. Ali, A.M.; Saber, G.E.; Mahfouz, N.M.; El-Gendy, M.A.; Radwan, A.A.; Hamid, M.A. Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. Arch. Pharm. Res., 2007, 30, 1186-1204.
71. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28, 235-242.
72. Puntambekar, D.S.; Giridhar, R.; Yadav, M.R. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors. Acta Pharm., 2006, 56, 157-174.
73. Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Giordani, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava, M. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J. Med. Chem., 2008, 51, 4476-4481.
74. Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Manetti, F.; Forli, S.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Makovec, F.; Giordani, A.; Anzellotti, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre, F.; Anzini, M.; Patrignani, P. Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. Bioorg. Med. Chem., 2008, 16, 8072-8081.
75. Rajakrishnan, V.; Manoj, V.R.; Subba Rao, G. Computer-aided, rational design of a potent and selective small peptide inhibitor of cyclooxygenase 2 (COX2). J. Biomol. Struct. Dyn., 2008, 25, 535-542.